Galera Therapeutics, Inc. (GRTX)
USD 0.02
(8.11%)
USD 0.02
(8.11%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 134.04 Million USD | 3274.85% |
| 2022 | -4.22 Million USD | 78.41% |
| 2021 | -19.55 Million USD | -27.51% |
| 2020 | -15.33 Million USD | 12.48% |
| 2019 | -17.52 Million USD | -424.0% |
| 2018 | 5.4 Million USD | 187.68% |
| 2017 | -6.16 Million USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | -9.55 Million USD | -106.88% |
| 2024 Q1 | 138.79 Million USD | 3.55% |
| 2023 Q4 | 134.04 Million USD | 680.44% |
| 2023 Q2 | -22.98 Million USD | -119.45% |
| 2023 Q1 | 118.17 Million USD | 2898.93% |
| 2023 FY | 134.04 Million USD | 3274.85% |
| 2023 Q3 | -23.09 Million USD | -0.49% |
| 2022 Q3 | -12.62 Million USD | 26.64% |
| 2022 Q1 | -19.41 Million USD | 0.75% |
| 2022 FY | -4.22 Million USD | 78.41% |
| 2022 Q4 | -4.22 Million USD | 66.55% |
| 2022 Q2 | -17.2 Million USD | 11.37% |
| 2021 Q1 | -13.15 Million USD | 14.23% |
| 2021 FY | -19.55 Million USD | -27.51% |
| 2021 Q4 | -19.55 Million USD | -13.37% |
| 2021 Q3 | -17.25 Million USD | 54.61% |
| 2021 Q2 | -38 Million USD | -188.91% |
| 2020 Q3 | -14.62 Million USD | 3.78% |
| 2020 Q2 | -15.2 Million USD | 27.0% |
| 2020 Q1 | -20.82 Million USD | -18.81% |
| 2020 FY | -15.33 Million USD | 12.48% |
| 2020 Q4 | -15.33 Million USD | -4.87% |
| 2019 FY | -17.52 Million USD | -424.0% |
| 2019 Q3 | -14.82 Million USD | 2.67% |
| 2019 Q2 | -15.23 Million USD | -118.68% |
| 2019 Q1 | 81.51 Million USD | 650.38% |
| 2019 Q4 | -17.52 Million USD | -18.22% |
| 2018 Q4 | -14.81 Million USD | 0.0% |
| 2018 FY | 5.4 Million USD | 187.68% |
| 2017 FY | -6.16 Million USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| America Great Health | 1.81 Million USD | -7280.672% |
| Ampio Pharmaceuticals, Inc. | -3.81 Million USD | 3613.552% |
| Aridis Pharmaceuticals, Inc. | 1.25 Million USD | -10589.155% |
| Biora Therapeutics, Inc. | 32.21 Million USD | -316.086% |
| Bio-Path Holdings, Inc. | -939 Thousand USD | 14374.973% |
| Better Therapeutics, Inc. | -860 Thousand USD | 15686.279% |
| Calithera Biosciences, Inc. | -23.78 Million USD | 663.557% |
| Comera Life Sciences Holdings, Inc. | 328.44 Thousand USD | -40711.592% |
| Gene Biotherapeutics, Inc. | - USD | -Infinity% |
| eFFECTOR Therapeutics, Inc. | 4.57 Million USD | -2833.085% |
| Eloxx Pharmaceuticals, Inc. | -5.82 Million USD | 2401.941% |
| Evelo Biosciences, Inc. | 3.19 Million USD | -4091.432% |
| Evolutionary Genomics, Inc. | 3.16 Million USD | -4132.886% |
| Finch Therapeutics Group, Inc. | 5 Million USD | -2579.768% |
| Innovation1 Biotech Inc. | 179.15 Thousand USD | -74721.1% |
| Kiromic BioPharma, Inc. | 12.33 Million USD | -986.372% |
| Molecular Templates, Inc. | 707 Thousand USD | -18859.264% |
| Navidea Biopharmaceuticals, Inc. | 438.44 Thousand USD | -30472.205% |
| NexImmune, Inc. | -3.13 Million USD | 4377.513% |
| Orgenesis Inc. | 21.78 Million USD | -515.323% |
| Panbela Therapeutics, Inc. | 2.61 Million USD | -5023.93% |
| Point of Care Nano-Technology, Inc. | -498.00 USD | 26916164.257% |
| PaxMedica, Inc. Common Stock | -4.71 Million USD | 2945.514% |
| Scopus BioPharma Inc. | -124.57 Thousand USD | 107699.438% |
| Sorrento Therapeutics, Inc. | 110.87 Million USD | -20.9% |
| Statera Biopharma, Inc. | 14.41 Million USD | -829.788% |
| TRACON Pharmaceuticals, Inc. | -7.59 Million USD | 1864.639% |
| Trevena, Inc. | 2.25 Million USD | -5836.315% |
| Vaxxinity, Inc. | 10.13 Million USD | -1222.957% |
| Vaccinex, Inc. | -1.28 Million USD | 10506.988% |
| Vicapsys Life Sciences, Inc. | 344.44 Thousand USD | -38815.244% |
| Viracta Therapeutics, Inc. | 13.23 Million USD | -912.478% |
| ZIVO Bioscience, Inc. | 71.96 Thousand USD | -186167.752% |